BioSpace News Archive

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT.

Xilio Therapeutics, Inc. announced pipeline progress and business updates and reported financial results for the first quarter ended March 31, 2024.

Kura Oncology, Inc today announced that it has completed enrollment of 85 patients in the Phase 2 portion of KOMET-001, a registration-directed clinical trial of the Company’s menin inhibitor, ziftomenib (KO-539), in patients with relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).

Vivos Therapeutics, Inc. today announced it plans to release its first quarter 2024 financial results after market close today, Tuesday, May 14, 2024.

MiNK Therapeutics, Inc. today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced topline data from a 12-week, randomized, double-blind, placebo-controlled trial of bexotegrast (PLN-74809) conducted at Massachusetts General Hospital evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF).

Pyxis Oncology, Inc. today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, announced the publication of a patient-focused global consensus statement – ‘Time to Act: A Global Patient-Focused Consensus for Improving the Care of Cutaneous T-Cell Lymphoma '.

Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.

Calliditas Therapeutics AB announces that its partner Everest Medicines has launched Nefecon® in China.